Delivery is one of the central components of every single gene therapy. It doesn’t matter how great the therapy is if it never gets inside the cell, or if they provoke a lethal immune response. Many delivery vectors are currently plagued with low organ-level precision, low efficiency, and/or high immunogenicity.
Incisive Genetics has secured the exclusive worldwide license from the University of British Columbia to the foundational Incisive Delivery System™ (IDS) and continues to build out its intellectual property and patent portfolio through additional research and development. Currently, we are focused on continued development of the IDS platform for therapeutic gene editing cargos.
We have undertaken key research activities to support the pre-clinical development of the Incisive Delivery System™, achieving significant proof of concept data for effective in vivo gene editing. We have approached our studies in a systematic way that enables us to iterate on our foundational system. We are actively using our platform to develop strategies for multiple disease indications, as well as creating new product modifications.
Gene editing is a completely new approach to disease management, and this therapeutic area is evolving at an incredibly rapid pace. Thanks to CRISPR technology, a simple yet powerful tool for editing genomes, science that was impossible in the past has now become reality. More than 7,000 monogenic diseases now have the potential to be treated using CRISPR technology.
However, other established CRISPR companies are currently using various delivery methods, each of which has multiple potential pitfalls. With delivery being a key component of every single gene therapy, success can only be achieved by offering a delivery vector that is highly efficient. This is where the Incisive Delivery System™ is set to disrupt and transform the field of CRISPR technology. The IDS platform enables a one-step encapsulation and safe, effective and efficient delivery of the key active CRISPR complex in a single package.